Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Atezolizumab in combination with Cobimetinib and Vemurafenib in patients with Melanoma.

Statements

Source and description
Tecentriq (atezolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.